|
PainCeptor Pharma Corporation |
|
|
7150, Albert-Einstein, Suite 100
St-Laurent, Quebec H4S 2C1 Canada
phone:(514) 337-5959
fax:(514) 337-8689
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.PainCeptor.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug development for the treatment of acute and chronic pain. |
|
| Management |
| Louis Lamontagne, President and CEO; Francine Gervais, Senior; Vice-President and Vice-President, Pharmaceutical Development; Kazimierz Babinski, Vice-President, Research; Marcus Brady, Vice-President, Business Development; Hugues Corbeil, Director, Finance And Operations |
| |
|
|
| |
|
| Keywords |
| pain, acute, chronic, ion channel, neurotrophin, neurotransmitter, receptor system, opioid, NSAID, acetaminophen |
|
|
|
| Description |
|
PainCeptor Pharma Corporation is focused on drug development for the treatment of acute and chronic pain. |
|
| Products / Services |
A number of neurotransmitter receptor systems, such as the ion channels and neurotrophins targeted by PainCeptor, have been identified as early targets in the pain cascade that may lead to novel drugs to replace or complement opioids, NSAIDs and acetaminophen. PainCeptor's drug development efforts will focus on 3 main programs revolving around ion channel and neurotrophin receptor targets.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members